Anlon Healthcare
- Market cap
- ₹ 1,359 Cr.
- P/E
- 45.6x
- P/B
- 5.62x
- 52-week range
- 10.37 – 37.24
- ROE
- 18%
- ROCE
- 21%
- Dividend yield
- 0%
- Debt / equity
- 0.19
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Anlon Healthcare Limited is an India-based company, which is engaged in the business of manufacturing of high purity advance pharmaceutical intermediates (Pharma Intermediate) which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients and active pharmaceutical ingredients (APIs) which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula (FDF), such as tablet, capsules, ointment, syrup, and ingredients in nutraceuticals formulations, personal care products and animal health products. Its products span across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API. Its products include 3-(1-cyanoethyl) benzoic acid (CEBA), ketoprofen ethyl ester (KEE), Dex-Ketoprofen, Loxoprofen Acid, Ketoprofen, Silodosin, Omeprazole, L-Arginine, Piroctone olamine, Ticagrelor, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Anlon Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)45.6 against a typical 34.3: pricier than most peers (1st = cheapest).147th of 220
- Sales growth+78.9% against a typical +15.6% from a year earlier.20th of 197
- Profit growth−50.3% against a typical +18.9% from a year earlier.134th of 160
- Share price, 3 months+53.7% against a typical −0.5%.12th of 200
- Size₹ 1,358.6 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).81st of 199
Latest announcements
Exchange filings and their impact on the company.
- Board approved Rs 250 crore preferential warrants to promoters and two public investors, a very large raise versus its size.
On October 13, 2026, Anlon Healthcare's board approved raising up to Rs 250 crore via warrants convertible into equity shares on a preferential basis. The warrants will be offered to two promoters, Punitkumar Rasadia and Meet Vachhani, and two public investors, Smart Horizon Capital and Ploutos Plus Consultant. Price and number of warrants will be decided later, with 25% payable on allotment and the rest on conversion within 18 months.
Fund raises
QIPs, preferential issues, warrants and rights issues, one row per filing, newest first. Open a row for details. All fund raise updates
| Stage | Details | |||||
|---|---|---|---|---|---|---|
| 13 Oct 2026 | Warrants | Board approved | ₹ 250 Cr. | — | — |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 13 Oct 2026 | Fund Raising/Other business matters | To consider Fund Raising and other business matters |
| 13 Aug 2026 | Other business matters | AHCL : 13-Aug-2026 : The Company has informed the Exchange that a Board meeting to be held on August 11, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on August 13, 2026, To consider other business matters |
| 11 Aug 2026 | Other business matters | To consider other business matters |
| 30 Jul 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 29 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 and and other business matters. |
| 6 Mar 2026 | Bonus | To consider stock split and bonus issue |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 49 | 33 | 36 | 51 | 88 |
| Expenses | 32 | 27 | 23 | 36 | 72 |
| Operating Profit | 17 | 6 | 12 | 15 | 16 |
| OPM % | 35.1% | 18.7% | 34.5% | 30.1% | 17.8% |
| Other Income | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 2 | 1 | 1 |
| Depreciation | 1 | 0 | 0 | 0 | 1 |
| Profit before tax | 15 | 5 | 11 | 14 | 14 |
| Tax % | −7.5% | 29.2% | 51.4% | 23.3% | 39.4% |
| Net Profit | 17 | 4 | 5 | 11 | 8 |
| EPS in Rs | 0.42 | 0.09 | 0.1 | 0.2 | 0.13 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 43%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 39%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Anlon Healthcare | ₹ 24.41 | ₹ 1,359 Cr. | 45.6x | 5.6x | 18% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Punitkumar R. Rasadia
- Executive Chairman of the Board, Managing Director
- Meet Atulkumar Vachhani
- Whole Time Director
- Amita Chhaganbhai Pragada
- Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.